1-12 of 12
S. Percy Ivy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative

Richard F. Little, Megan Othus, Sarit Assouline, Sherry Ansher, Ehab L. Atallah, R. Coleman Lindsley, Boris Freidlin, Steven D. Gore, Lyndsay Harris, Christopher S. Hourigan, S. Percy Ivy, Shahanawaz Jiwani, Erin Langan, Selina M. Luger, Laura C. Michaelis, Olatoyosi Odenike, David Patton, Miguel-Angel Perales, Jerald P. Radich, Bhanu Ramineni, Jesse J. Salk, Patrick Stiff, Wendy Stock, Richard M. Stone, Geoffrey L. Uy, P. Mickey Williams, Brent L. Wood, Katherine H Worthington, Laura M Yee, Amer M. Zeidan, Jianqiao Zhang, Mark R. Litzow, Harry P. Erba
Journal: Blood
Blood (2022) 140 (Supplement 1): 9057–9060.
https://doi.org/10.1182/blood-2022-169307
Published: 2022
Journal Articles

Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia

Kerry A. Rogers, Eric McLaughlin, Lai Wei, Mirela Iulia Anghelina, Mir Khader Ali, Leslie A. Andritsos, Evgeny Arons, James S. Blachly, Timothy G. Call, S. Percy Ivy, Lacey James-Echenique, Jeffrey A. Jones, Robert J. Kreitman, Gerard Lozanski, Farhad Ravandi, Charles A. Schiffer, William E. Carson, III, Michael R. Grever
Journal: Blood
Blood (2022) 140 (Supplement 1): 6494–6495.
https://doi.org/10.1182/blood-2022-165795
Published: 2022
Journal Articles

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

Clinical Trials & Observations
Kerry A. Rogers, Leslie A. Andritsos, Lai Wei, Eric M. McLaughlin, Amy S. Ruppert, Mirela Anghelina, James S. Blachly, Timothy Call, Dai Chihara, Anees Dauki, Ling Guo, S. Percy Ivy, Lacey R. James, Daniel Jones, Robert J. Kreitman, Gerard Lozanski, David M. Lucas, Apollinaire Ngankeu, Mitch Phelps, Farhad Ravandi, Charles A. Schiffer, William E. Carson, III, Jeffrey A. Jones, Michael R. Grever
Journal: Blood
Blood (2021) 137 (25): 3473–3483.
https://doi.org/10.1182/blood.2020009688
Published: 2021
Includes: Supplemental data
Journal Articles

Phase 1 Study of Escalating Doses of Ibrutinib and Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) with Isavuconazole for Relapsed and Refractory Primary CNS Lymphoma

Mark Roschewski, MD, Christopher Melani, MD, Rahul Lakhotia, MD, Stefania Pittaluga, MD PhD, James D. Phelan, PhD, Cody Peer, PhD, Michail S. Lionakis, MD ScD, Lydia L. Chou, CRNP, Matthias Holdhoff, MD PhD, Michael Glantz, MD PhD, Jan Drappatz, MD, Catherine Lai, MD MPH, John A. Butman, MD PhD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, William D. Figg, PhD, Elaine S. Jaffe, MD, S. Percy Ivy, MD, Richard F. Little, MDMPH, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 12–13.
https://doi.org/10.1182/blood-2020-137637
Published: 2020
Journal Articles

Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy

Amer M. Zeidan, MBBS, MHS, Prajwal Boddu, MD, Brent L Wood, MD PhD, Daniel Zelterman, Richard F. Little, MDMPH, S. Percy Ivy, MD, Anne Caldwell, Beatriz Sanchez-Espiridion, Gheath Alatrash, Elad Sharon, MD MPH, Jerald P. Radich, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–12.
https://doi.org/10.1182/blood-2020-139752
Published: 2020
Journal Articles

Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Prajwal C Boddu, MBBS, Brent L Wood, MD PhD, Daniel Zelterman, Richard F. Little, MDMPH, S. Percy Ivy, MD, Anne Caldwell, Beatriz Sanchez-Espiridion, Gheath Alatrash, Elad Sharon, MD MPH, Jerald P. Radich, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 15.
https://doi.org/10.1182/blood-2020-139668
Published: 2020
Journal Articles

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Namrata S Chandhok, MD, Wei Wei, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD, Yu Shyr, Jing Li, PhD, Michael Berens, PhD, Chris Karlovich, PhD, S. Percy Ivy, MD, Thomas Prebet, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3909.
https://doi.org/10.1182/blood-2019-129168
Published: 2019
Journal Articles

A Comprehensive Assessment of Phase 1 Clinical Trials in Acute Myeloid Leukemia

Joshua F. Zeidner, MD, Judith E. Karp, MD, Amanda Blackford, Jose Mejias, Gary Smith, S. Percy Ivy, MD, Pamela Harris, MD
Journal: Blood
Blood (2014) 124 (21): 2282.
https://doi.org/10.1182/blood.V124.21.2282.2282
Published: 2014
Journal Articles

Clinical and Biologic Activity of the Heat Shock Protein-90 (HSP-90) Inhibitor 17-AAG in Patients with Relapsed Lymphoma.

Anas Younes, MD, Amanda R Copeland, MS, Jorge Romaguera, MD, Luis Fayad, MD, Michelle Fanale, M.D., Silvana de Castro Faria, MD, PhD, L. Jeffrey Medeiros, MD, Ph.D, S. Percy Ivy, MD
Journal: Blood
Blood (2009) 114 (22): 3744.
https://doi.org/10.1182/blood.V114.22.3744.3744
Published: 2009
Journal Articles

Sunitinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: Results of a Phase II Multi-Center Study of the NCIC Clinical Trials Group.

Rena Buckstein, MD, John Kuruvilla, MD, Neil Chua, MD, Christina Lee, David A Macdonald, MD, Abdulwahab J. Al-Tourah, MD, Alison Foo, Wendy Walsh, S. Percy Ivy, MD, Michael Crump, MD, Elizabeth Eisenhauer, MD
Journal: Blood
Blood (2009) 114 (22): 2729.
https://doi.org/10.1182/blood.V114.22.2729.2729
Published: 2009
Journal Articles

The Geldanamycin Derivative DMAG Demonstrates Improved Cytotoxicity and Down-Modulation of Hsp90 Client Proteins Relative to 17-AAG in Chronic Lymphocytic Leukemia (CLL) Cells: Justification for Clinical Trials in CLL.

Amy J. Johnson, PhD, Amy J. Wagner, BA, Lisa L. Smith, MS, David M. Lucas, PhD, Michael D. De Lay, BA, Jamie M. Allison, BA, S. Percy Ivy, MD, Thomas S. Lin, MD,PhD, John C. Byrd, MD
Journal: Blood
Blood (2006) 108 (11): 2101.
https://doi.org/10.1182/blood.V108.11.2101.2101
Published: 2006
Journal Articles

Molecular Mechanism of Antifolate Transport-Deficiency in a Methotrexate-Resistant MOLT-3 Human Leukemia Cell Line

Maokai Gong, James Yess, Tatiana Connolly, S. Percy Ivy, Takao Ohnuma, Kenneth H. Cowan, Jeffrey A. Moscow
Journal: Blood
Blood (1997) 89 (7): 2494–2499.
https://doi.org/10.1182/blood.V89.7.2494
Published: 1997